Erlizumab is a humanized monoclonal antibody directed against the integrin beta-2 subunit (CD18). By blocking the interaction between CD18 on leukocytes and adhesion molecules on vascular endothelial cells, this antibody effectively inhibits inflammatory cell recruitment and infiltration, thereby reducing tissue damage in myocardial reperfusion injury.
CAS Number:
[211323-03-4]
Target:
Integrin
* VAT and and shipping costs not included. Errors and price changes excepted
